{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:06:13Z","timestamp":1790910373343,"version":"4.1.0"},"reference-count":22,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,1,23]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>In a 3-year follow-up of the DASatinib versus Imatinib Study In treatment-Naive CML patients trial, first-line dasatinib resulted in faster and deeper responses compared with imatinib. Deeper responses at 3, 6, and 12 months were associated with better 3-year progression-free survival and overall survival.<\/jats:p>","DOI":"10.1182\/blood-2013-06-511592","type":"journal-article","created":{"date-parts":[[2013,12,5]],"date-time":"2013-12-05T23:58:51Z","timestamp":1386287931000},"page":"494-500","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":344,"title":["Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)"],"prefix":"10.1182","volume":"123","author":[{"given":"Elias","family":"Jabbour","sequence":"first","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Saglio","sequence":"additional","affiliation":[{"name":"University of Torino, Ospedale San Luigi Gonzaga, Orbassano-Torino, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Luis","family":"Steegmann","sequence":"additional","affiliation":[{"name":"Hospital de la Princesa, Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil P.","family":"Shah","sequence":"additional","affiliation":[{"name":"University of California, San Francisco School of Medicine, San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concepci\u00f3n","family":"Boqu\u00e9","sequence":"additional","affiliation":[{"name":"Department of Clinical Hematology, Institut Catal\u00e0 d\u2019Oncologia, Hospitalet de Llobregat, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Chuah","sequence":"additional","affiliation":[{"name":"Singapore General Hospital and Duke-National University of Singapore Graduate Medical School, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Pavlovsky","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Para Combatir la Leucemia, Angelica Ocampo Hospitalization and Clinical Research Center, Buenos Aires, Argentina;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u0159\u00ed","family":"Mayer","sequence":"additional","affiliation":[{"name":"University Hospital Brno and Central European Institute of Technology Masaryk University, Brno, Czech Republic;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Baccarani","sequence":"additional","affiliation":[{"name":"University of Bologna, Bologna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Wook","family":"Kim","sequence":"additional","affiliation":[{"name":"The Catholic University of Korea, Seoul, Korea;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Brigid","family":"Bradley-Garelik","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Wallingford, CT;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Princeton, NJ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Wildgust","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Princeton, NJ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Jena, Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"24","key":"2019111818485083600_B1","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"issue":"15 suppl","key":"2019111818485083600_B2","article-title":"Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up. [abstract].","volume":"30","author":"Hochhaus","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111818485083600_B3","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1038\/sj.leu.2402680","article-title":"Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.","volume":"16","author":"Merx","year":"2002","journal-title":"Leukemia"},{"issue":"6","key":"2019111818485083600_B4","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1046\/j.1365-2141.2003.04200.x","article-title":"The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia.","volume":"120","author":"Wang","year":"2003","journal-title":"Br J Haematol"},{"issue":"25","key":"2019111818485083600_B5","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1182\/blood-2008-07-166694","article-title":"Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy.","volume":"113","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2019111818485083600_B6","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/blood-2006-02-004325","article-title":"Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.","volume":"108","author":"Kantarjian","year":"2006","journal-title":"Blood"},{"issue":"12","key":"2019111818485083600_B7","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","article-title":"European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.","volume":"112","author":"Marin","year":"2008","journal-title":"Blood"},{"issue":"17","key":"2019111818485083600_B8","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1182\/blood-2011-04-348110","article-title":"The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors.","volume":"118","author":"Jabbour","year":"2011","journal-title":"Blood"},{"issue":"19","key":"2019111818485083600_B9","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"issue":"15","key":"2019111818485083600_B10","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"issue":"32","key":"2019111818485083600_B11","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1200\/JCO.2011.36.0693","article-title":"Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?","volume":"29","author":"Jabbour","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111818485083600_B12","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2012-01-407486","article-title":"Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib.","volume":"120","author":"Marin","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2019111818485083600_B13","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2019111818485083600_B14","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa.","volume":"90","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"2019111818485083600_B15","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2019111818485083600_B16","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"issue":"1 Suppl","key":"2019111818485083600_B17","doi-asserted-by":"crossref","first-page":"14S","DOI":"10.1378\/chest.126.1_suppl.14S","article-title":"Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.","volume":"126","author":"McGoon","year":"2004","journal-title":"Chest"},{"issue":"20","key":"2019111818485083600_B18","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/eurheartj\/ehp297","article-title":"Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).","volume":"30","author":"Gali\u00e8","year":"2009","journal-title":"Eur Heart J"},{"issue":"24","key":"2019111818485083600_B19","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1182\/blood-2013-03-490128","article-title":"Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities.","volume":"121","author":"Jain","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2019111818485083600_B20","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"issue":"3","key":"2019111818485083600_B21","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.","volume":"30","author":"Marin","year":"2012","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111818485083600_B22","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","article-title":"Tolerability-adapted imatinib 800 mg\/d versus 400 mg\/d versus 400 mg\/d plus interferon-\u03b1 in newly diagnosed chronic myeloid leukemia.","volume":"29","author":"Hehlmann","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/123\/4\/494\/1378207\/494.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/123\/4\/494\/1378207\/494.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T18:49:01Z","timestamp":1574102941000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/123\/4\/494\/32285\/Early-response-with-dasatinib-or-imatinib-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,23]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,1,23]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2013-06-511592","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,23]]}}}